Literature DB >> 28182587

Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics.

Emina E Torlakovic1, Carol C Cheung, Corrado D'Arrigo, Manfred Dietel, Glenn D Francis, C Blake Gilks, Jacqueline A Hall, Jason L Hornick, Merdol Ibrahim, Antonio Marchetti, Keith Miller, J Han van Krieken, Soren Nielsen, Paul E Swanson, Mogens Vyberg, Xiaoge Zhou, Clive R Taylor.   

Abstract

All laboratory tests have test performance characteristics (TPCs), whether or not they are explicitly known to the laboratorian or the pathologist. TPCs are thus also an integral characteristic of immunohistochemistry (IHC) tests and other in situ, cell-based molecular assays such as DNA or RNA in situ hybridization or aptamer-based testing. Because of their descriptive, in situ, cell-based nature, IHC tests have a limited repertoire of appropriate TPCs. Although only a few TPCs are relevant to IHC, proper selection of informative TPCs is nonetheless essential for the development of and adherence to appropriate quality assurance measures in the IHC laboratory. This paper describes the TPCs that are relevant to IHC testing and emphasizes the role of TPCs in the validation of IHC tests. This is part 2 of the 4-part series "Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine."

Mesh:

Year:  2017        PMID: 28182587     DOI: 10.1097/PAI.0000000000000444

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  12 in total

1.  A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.

Authors:  Steven A Bogen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-02-22

Review 2.  Fit-for-Purpose Immunohistochemical Biomarkers.

Authors:  Emina Emilia Torlakovic
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

3.  Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area.

Authors:  Andra-Iulia Suceveanu; Ioan Sergiu Micu; Gabriela-Izabela Baltatescu; Lucian Cristian Petcu; Nicolae Dobrin; Costel Brinzan; Cornelia Nitipir; Laura Mazilu; Florin Botea; Vlad Herlea; Felix Voinea; Adrian Paul Suceveanu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

Review 4.  [Interlaboratory comparisons-a central means of external quality assurance].

Authors:  Korinna Jöhrens; Maja Grassow; Gustavo Baretton; Florian Sperling
Journal:  Pathologie (Heidelb)       Date:  2022-08-10

5.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

6.  The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols.

Authors:  Bin Xu; Samira Alminawi; Patrice Boulianne; Yan Ming Shang; Michelle R Downes; Elzbieta Slodkowska
Journal:  Virchows Arch       Date:  2020-11-11       Impact factor: 4.064

Review 7.  Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.

Authors:  Sylvie Lantuejoul; Francesca Damiola; Julien Adam
Journal:  Transl Lung Cancer Res       Date:  2020-06

8.  An Image Analysis Solution For Quantification and Determination of Immunohistochemistry Staining Reproducibility.

Authors:  Elizabeth A Chlipala; Christine M Bendzinski; Charlie Dorner; Raili Sartan; Karen Copeland; Roger Pearce; Faye Doherty; Brad Bolon
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020-07

Review 9.  Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL.

Authors:  K Dufraing; F Fenizia; E Torlakovic; N Wolstenholme; Z C Deans; E Rouleau; M Vyberg; S Parry; E Schuuring; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2020-10-13       Impact factor: 4.064

10.  Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).

Authors:  Carol C Cheung; Penny Barnes; Gilbert Bigras; Scott Boerner; Jagdish Butany; Fiorella Calabrese; Christian Couture; Jean Deschenes; Hala El-Zimaity; Gabor Fischer; Pierre O Fiset; John Garratt; Laurette Geldenhuys; C Blake Gilks; Marius Ilie; Diana Ionescu; Hyun J Lim; Lisa Manning; Adnan Mansoor; Robert Riddell; Catherine Ross; Sinchita Roy-Chowdhuri; Alan Spatz; Paul E Swanson; Victor A Tron; Ming-Sound Tsao; Hangjun Wang; Zhaolin Xu; Emina E Torlakovic
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019 Nov/Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.